{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:56:37Z","timestamp":1793422597988,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.biopha.2022.113839","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T01:16:35Z","timestamp":1665450995000},"page":"113839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy"],"prefix":"10.1016","volume":"156","author":[{"given":"Edwin A.","family":"Basak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlijn","family":"de Joode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom J.J.","family":"Uyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"van der Wal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco W.J.","family":"Schreurs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd A.A.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Oomen-de Hoop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cor H.","family":"van der Leest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layal","family":"Chaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Feelders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid A.M.","family":"van der Veldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjen","family":"Joosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn L.W.","family":"Koolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim G.J.V.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Bins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.biopha.2022.113839_bib1","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med"},{"issue":"26","key":"10.1016\/j.biopha.2022.113839_bib2","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"K.-. investigators, Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.biopha.2022.113839_bib3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med"},{"issue":"11","key":"10.1016\/j.biopha.2022.113839_bib4","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"K.-. Investigators, Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"19","key":"10.1016\/j.biopha.2022.113839_bib5","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"I. CheckMate, Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med"},{"issue":"19","key":"10.1016\/j.biopha.2022.113839_bib6","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"suppl_4","key":"10.1016\/j.biopha.2022.113839_bib7","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"E.G. Committee, Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2022.113839_bib8","doi-asserted-by":"crossref","first-page":"k4226","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"Bmj"},{"key":"10.1016\/j.biopha.2022.113839_bib9","first-page":"966","article-title":"Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients","volume":"30","author":"Basak","year":"2020"},{"issue":"8","key":"10.1016\/j.biopha.2022.113839_bib10","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2022.113839_bib11","doi-asserted-by":"crossref","unstructured":"N. Youssef, M. Noureldein, G. Daoud, A.A. Eid, Immune checkpoint inhibitors and diabetes: Mechanisms and predictors, Diabetes Metab (2020).","DOI":"10.1016\/j.diabet.2020.09.003"},{"issue":"11","key":"10.1016\/j.biopha.2022.113839_bib12","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00262-017-2033-8","article-title":"Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review","volume":"66","author":"Gauci","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.biopha.2022.113839_bib13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"de Filette","year":"2019","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113839_bib14","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s13340-018-0362-2","article-title":"R. consultation of the Japan Diabetes Society Committee on Type 1 Diabetes Mellitus, Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy","volume":"10","author":"Baden","year":"2019","journal-title":"Diabetol. Int"},{"issue":"2016)","key":"10.1016\/j.biopha.2022.113839_bib15","article-title":"Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma","author":"Aleksova","year":"2016","journal-title":"BMJ Case Rep."},{"issue":"7","key":"10.1016\/j.biopha.2022.113839_bib16","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/dme.12159","article-title":"The clinical utility of C-peptide measurement in the care of patients with diabetes","volume":"30","author":"Jones","year":"2013","journal-title":"Diabet. Med"},{"issue":"2","key":"10.1016\/j.biopha.2022.113839_bib17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11154-020-09618-w","article-title":"Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature","volume":"22","author":"Lo Preiato","year":"2021","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"4","key":"10.1016\/j.biopha.2022.113839_bib18","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.pan.2019.04.015","article-title":"Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis","volume":"19","author":"George","year":"2019","journal-title":"Pancreatology"},{"issue":"6","key":"10.1016\/j.biopha.2022.113839_bib19","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2022.113839_bib20","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.2337\/dc18-1673","article-title":"Detailed Time Course of Decline in Serum C-Peptide Levels in Anti-Programmed Cell Death-1 Therapy-Induced Fulminant Type 1 Diabetes","volume":"42","author":"Saito","year":"2019","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.biopha.2022.113839_bib21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s13300-017-0265-4","article-title":"A Practical Review of C-Peptide Testing in Diabetes","volume":"8","author":"Leighton","year":"2017","journal-title":"Diabetes Ther."},{"issue":"8","key":"10.1016\/j.biopha.2022.113839_bib22","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.semcdb.2010.07.007","article-title":"Pancreatic beta-cells: from generation to regeneration","volume":"21","author":"Collombat","year":"2010","journal-title":"Semin Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113839_bib23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1210\/jc.2009-1365","article-title":"Clinical applications of diabetes antibody testing","volume":"95","author":"Bingley","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.biopha.2022.113839_bib24","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.2337\/dc20-0609","article-title":"Immune Checkpoint Inhibitor-Associated Diabetes: A Single-Institution Experience","volume":"43","author":"Byun","year":"2020","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.biopha.2022.113839_bib25","doi-asserted-by":"crossref","first-page":"R38","DOI":"10.1530\/EC-17-0347","article-title":"On type 1 diabetes mellitus pathogenesis","volume":"7","author":"Paschou","year":"2018","journal-title":"Endocr. Connect"},{"key":"10.1016\/j.biopha.2022.113839_bib26","unstructured":"J.S. Bryan, N. Jarushka, D.S.. Bianca, L.. Christina, A. Sherry, A. Milan, B.A. Michael, J.B. Kelly, M.C. Jeffrey, C. Ian, J.D. Marianne, S.E. Marc, F. Leslie, G. Monalisa, J. Ishmael, S.M. Jennifer, N. Aung, J.N. Loretta, P. Tanyanika, D.P. Laura, A.R. Cristina, S. Carole, S. Jung-Min, S. Alexander, S.-A. Maria, S. Umang, A.T. John, V. Praveen, W. Yinghong, S.W. Jeffrey, F. Pauline, B. Kathryn, Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update, Journal of Clinical Oncology 0(0) JCO.21.01440."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222012288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222012288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:07:01Z","timestamp":1778242021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222012288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":26,"alternative-id":["S0753332222012288"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113839","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113839","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113839"}}